This site is part of the Global Exhibitions Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 3099067.


Key Regulatory Issues for Dengue Vaccine Development

In this week's PLoS Medicine, Richard Mahoney and colleagues discuss two recent meetings convened by the Pediatric Dengue Vaccine Initiative and the Developing Countries' Vaccine Regulators Network on regulatory issues that need to be addressed before licensing dengue vaccines.

This work was supported by Bill & Melinda Gates Foundation grant# 23197. The

Reference: Mahoney R, Chocarro L, Southern J, Francis DP, Vose J, et al. (2011) Dengue Vaccines Regulatory Pathways: A Report on Two Meetings with Regulators of Developing Countries. PLoS Med 8(2): e1000418.doi:10.1371/journal.pmed.1000418

comments powered by Disqus